Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting
Rhea-AI Summary
Aurora Spine (OTCQB: ASAPF) will exhibit at the North American Spine Society (NASS) Annual Meeting from November 14–16, 2025 at the Colorado Convention Center in Denver.
Visit Booth #1622 to see live demonstrations of the newly launched Hydra facet fusion system and DEXA-L anterior lumbar interbody fusion device, part of Aurora’s patented DEXA Technology Platform that offers patient-matched implants aligned to bone density and T-Score.
Company leaders Trent Northcutt (CEO) and Laszlo Garamszegi (CTO) will highlight the products' design goals and clinical relevance for spine surgeons and attendees.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ASAPF declined 1.21%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to Showcase Cutting-Edge Innovations at Booth #1622
CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its participation at the 2025 North American Spine Society ("NASS") Annual Meeting. The event will take place from November 14-16, 2025, at the Colorado Convention Center, in Denver, Colorado. Aurora Spine will be exhibiting at Booth #1622.
The North American Spine Society is a global multidisciplinary medical society that utilizes education, research, and advocacy to foster the highest quality, ethical, and evidence-based spine care. NASS gathers spine professionals from around the world, offering a unique platform for Aurora to showcase its latest innovations.
At this year’s event, the company will feature its newly launched Hydra ANATOMIC. ELEVATED. RIGID. OSTEOFIXATION Facet Fusion System for facet joint-related pain or instability and DEXA-L, a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures, which is part of Aurora’s patented DEXA™ Technology Platform, which offers patient-matched implants designed to align with individual bone density and T-Score, ushering in a new era of personalized spinal care.
“We are excited to attend NASS 2025 and to showcase our cutting-edge, proprietary products we've developed, especially the recently launched Hydra and DEXA-L product lines,” said Trent Northcutt, President and CEO of Aurora Spine. "We’ve worked diligently to bring new, proprietary technologies to market that are transforming spinal surgery, and we can’t wait to share them with the industry at NASS 2025."
Laszlo Garamszegi, Chief Technology Officer, added: "We’re particularly excited to showcase the DEXA-L implant line, which is the first of its kind in the world and is the first spinal implant that is a bone-mimicking™ structural implant helping doctors match the implant to the patient’s bone density and quality. These products are game-changing for spine surgeons and their patients, and we are proud to be presenting them at NASS 2025 and connecting with industry professionals in attendance."
Visit Aurora Spine at Booth #1622 to witness live demonstrations and engage with the team on how these innovations are reshaping spinal surgery.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
Investor Relations
Adam Lowensteiner
Lytham Partners
Phone: (646) 829-9702
Email: asapf@lythampartners.com
FAQ
When and where will Aurora Spine (ASAPF) exhibit at NASS 2025?
What booth number will Aurora Spine (ASAPF) be at during NASS 2025?
Which new products will Aurora Spine (ASAPF) showcase at NASS 2025?
What is DEXA-L and why is Aurora Spine (ASAPF) highlighting it at NASS 2025?
Who from Aurora Spine (ASAPF) will speak about the new products at NASS 2025?
